On-Demand Webinar

Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human

Watch the webinar to learn how QSP and a model-informed target product profile guide indication,…

Danielle PillsburyOctober 9, 2026

Publication

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma

Explore a simultaneous population PK/PD model characterizing the dynamic relationships between belantamab mafodotin, sBCMA, and…

CertaraOctober 5, 2026

Conference

2nd TCE for Autoimmune Disease Summit

–

Danielle PillsburyOctober 5, 2026

Publication

Modeling effective doses of therapeutic antibodies targeting clustered surface receptors

Discover how semi-mechanistic PK/receptor-occupancy modeling reveals that lower, subcutaneous doses, not maximum tolerated doses, optimize…

Danielle PillsburySeptember 23, 2026

White Paper

Model-Informed Strategies for ADC Development

Explore how model informed drug development can help ADC developers optimize dosing, reduce uncertainty, strengthen…

Danielle PillsburySeptember 22, 2026

Publication

Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate

See how QSP modeling guided the design of a reversible antibody switch that unmasks IL-12…

CertaraJuly 24, 2026

Poster

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

See how quantitative pharmacology and PBPK modeling supported first in human dose selection for a…

CertaraJuly 20, 2026

Publication

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

QSP modeling reveals patient-specific factors driving CAR T-cell response and relapse in multiple myeloma, with…

CertaraJuly 20, 2026

On-Demand Webinar

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Watch this on-demand Q&A on using mechanistic modeling to assess feasibility and prioritize biotherapeutic candidates…

CertaraJuly 17, 2026

On-Demand Webinar

Integrated mechanistic modeling approaches in oncology drug development

Learn how integrated QSP and PBPK modeling supports dose justification, patient stratification, and regulatory decisions…

CertaraJuly 8, 2026

Biologics

Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma

2nd TCE for Autoimmune Disease Summit

Modeling effective doses of therapeutic antibodies targeting clustered surface receptors

Model-Informed Strategies for ADC Development

Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Integrated mechanistic modeling approaches in oncology drug development

Newsletter sign up

Quick links

Solutions

Contact